Moreover, studies have reported the overexpression of SPP enzymes in various types of cancers (breast cancers–including TNBC—melanoma, colon cancer, glioma, cervical adenocarcinoma, lung and thyroid cancers, and leukemia) associated with the genomic amplification of PHGDH, with resistance to therapy [14,15,16] and generally a more aggressive pathology [15,16,17,18,19,20]. This evidence concerns the gene PHGDH and cancer.